Lurasidone Linked to Relatively Low Risk for Metabolic Syndrome in Bipolar Depression
Investigators analyzed the potential metabolic effects of lurasidone in a sample of patients with bipolar I depression.
Investigators analyzed the potential metabolic effects of lurasidone in a sample of patients with bipolar I depression.
Patients may be at risk for increased comorbidity burden after a diagnosis of binge eating disorder.
There is enormous need for well-trained providers who are educated in treating opioid use disorder.
At Psych Congress 2018, Andrew Penn from the UCSF School of Nursing provides insight into the use of CBD in clinical practice.
MDMA-assisted psychotherapy has demonstrated early success in PTSD in multiple phase 2 trials.
Researchers evaluated the efficacy and safety of trace amine associated receptor-1 agonist SEP-363856 in patients with schizophrenia.
If approved, HP-3070 would be the first transdermal antipsychotic available in the United States, and would provide a novel, safe, and efficacious treatment delivery system for adult patients with schizophrenia.
Treatment with lofexidine may provide better control of the symptoms of opioid withdrawal syndrome compared with placebo.
Over the course of 52 weeks, a combination of olanzapine and samidorphan was associated with minimal weight gain, tolerable adverse events, and durable antipsychotic effects in patients with schizophrenia.
Researchers sought to document and describe the contributions of certified PAs across practice areas in addressing mental health conditions.